New Age Alpha Advisors LLC Invests $1.49 Million in Artivion, Inc. (NYSE:AORT)

New Age Alpha Advisors LLC bought a new stake in Artivion, Inc. (NYSE:AORT) in the 4th quarter, Holdings Channel.com reports. The firm bought 52,223 shares of the company’s stock, valued at approximately $1,493,000.

Several other hedge funds have also bought and sold shares of the company. Intech Investment Management LLC raised its stake in Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock valued at $280,000 after buying an additional 653 shares during the period. The Manufacturers Life Insurance Company raised its stake in Artivion by 28.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock valued at $522,000 after acquiring an additional 4,295 shares during the period. FMR LLC lifted its holdings in Artivion by 28.0% during the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after purchasing an additional 25,176 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Artivion by 543.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock valued at $761,000 after purchasing an additional 24,130 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after purchasing an additional 125,668 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AORT shares. Needham & Company LLC dropped their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $31.40.

Insider Activity

In other Artivion news, insider John E. Davis sold 15,100 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the transaction, the insider now directly owns 208,778 shares of the company’s stock, valued at $4,929,248.58. This trade represents a 6.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares of the company’s stock, valued at $18,130,617.42. The trade was a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is currently owned by company insiders.

Artivion Price Performance

Shares of Artivion stock opened at $24.26 on Monday. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1,212.80 and a beta of 1.79. Artivion, Inc. has a twelve month low of $19.36 and a twelve month high of $32.33. The company has a 50-day simple moving average of $27.58 and a two-hundred day simple moving average of $27.65.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.